Parkside Financial Bank & Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

Parkside Financial Bank & Trust’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.01K	Sell	48 -84	-64%	-$1.89K	﹤0.01%	2355
2025 Q4	$3.04K	Hold	132	–	–	﹤0.01%	1961
2025 Q3	$3.97K	Buy	132 +121	+1,100%	+$3.63K	﹤0.01%	1802
2025 Q2	$400	Buy	+11	New	+$397	﹤0.01%	2620
2025 Q1	–	Sell	-6	Closed	-$253	–	2757
2024 Q4	$253	Buy	+6	New	+$298	﹤0.01%	2017
2023 Q3	–	Sell	-80	Closed	-$3.69K	–	2098
2023 Q2	$3.69K	Hold	80	–	–	﹤0.01%	1475
2023 Q1	$3.21K	Hold	80	–	–	﹤0.01%	1527
2022 Q4	$3.71K	Buy	+80	New	+$3.15K	﹤0.01%	1445
2022 Q3	–	Sell	-11	Closed	-$1K	–	1917
2022 Q2	$1K	Buy	+11	New	+$677	﹤0.01%	1749
2022 Q1	–	Sell	-2	Closed	–	–	1915
2021 Q4	$0	Sell	2 -3	-60%	-$244	﹤0.01%	1901
2021 Q3	$0	Buy	+5	New	+$452	﹤0.01%	1831

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Parkside Financial Bank & Trust's RARE Position: Q1 2026 in Review

Parkside Financial Bank & Trust reduced its Ultragenyx Pharmaceutical (RARE) stake by 64% in Q1 2026, selling an estimated $1.89K and leaving 48 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #2355.

Parkside Financial Bank & Trust first reported a position in RARE in Q3 2021 and has held it in 11 quarters since. The position peaked at $3.97K in Q3 2025. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

Parkside Financial Bank & Trust held 48 shares of Ultragenyx Pharmaceutical worth $1.01K as of Q1 2026.
Parkside Financial Bank & Trust sold 84 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $1.89K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #2355 holding.
Parkside Financial Bank & Trust first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and has held it in 11 quarters since.
Parkside Financial Bank & Trust's Ultragenyx Pharmaceutical position peaked at $3.97K in Q3 2025.
296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.